Tag: stock option

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that it will present at the OTCQB Venture Virtual Investor Conference on August 7^th, 2025.

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.

WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective August 1, 2025, the company granted non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BELLINGHAM, Wash., July 31, 2025 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises,, today announced financial results for the second quarter ended June 30, 2025.

CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) -- Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC) announces that the Kavango West 1X exploration well is currently drilling and provides a corporate update on ongoing operations.